Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis
- 716 Downloads
Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.
KEY WORDSprolyl hydroxylases inflammatory bowel disease colitis disease activity index
Hypoxia-inducible factor (HIF)-prolyl hydroxylases (PHDs) are members of the dioxygenase enzymes family. These enzymes are known to play an important function in intracellular oxygen sensing as well as signalling responses in low oxygen levels (hypoxia). This occurs mainly by the regulation of HIF stability [1, 2, 3, 4]. These PHDs consist of three isoforms (PHD-1, PHD-2 and PHD-3), which share mostly similar biochemical characteristics; however, all three isoforms of PHDs are known to have very distinct and tissue-specific expression profiles and, regulation of HIF, which in turn can affect pro-survival signalling pathways, including nuclear factor κB pathways during inflammation [1, 5, 6, 7]. These PHDs are known to mediate their effect on HIF pathway via hydroxylation of proline residues of the HIFα subunit, which is degraded under normoxic condition. Once it is hydroxylated, HIFα acts as a target for ubiquitylation by von Hipple Lindau E3 ubiquititin ligase and results in the degradation and ubiquitination of HIFα . The PHDs perform a pivotal function in an adaptive response known to occur during hypoxia via the activation of several pathways of genes expression implicated in support of cell survival, erythropoiesis, angiogenesis and metabolism. These features make PHD an interesting target for therapy .
Inflammatory bowel disease (IBD), an idiopathic disease with genetically heterogenous nature, has chronic inflammatory conditions in the gastrointestinal tract (GIT) with severe pathology and limited therapeutic options [10, 11, 12]. To date, the underlying causes of IBD are not well-defined; however, the fundamental defect in this disease involves damage/injury of the intestinal epithelial barrier resulting in the development and progression of the disease. Hence, targeting the HIF-PHD pathway may be a fascinating area for potential future therapeutics for inflammatory disease.
Various reports employing pharmacological inhibition of hydroxylase enzyme revealed improvisation in a variety of inflammatory conditions including IBD [13, 15]. Several researchers reported that pan-hydroxylase inhibitors such as dimethyloxalylglycine (DMOG) have a protective effect in experimental colitis [13, 14, 15]. However, the majority of these studies have not identified the actual isoform of PHDs or the effector pathways involved in this protective effect.
Our previous findings suggested that there was an increased PHD-1 level in patients with active ulcerative colitis and genetic loss of PHD-1 was found to be protective in experimental colitis . However, since there are three isoforms of PHDs, it would be of interest for researchers to know how the levels of PHDs change during disease development and recovery in IBD. Thus, to answer this query, the present study has been framed to examine the changes in levels of PHDs (PHD-1, -2 and -3) during the inflammation development and its progression in an experimental model of murine colitis.
MATERIALS AND METHODS
Dextran Sodium Sulphate (DSS)-Induced Colitis
Colitis was induced in female C57/Bl6 mice using our previously established protocol [15, 17]. Briefly, 2.5 % w/v dextran sodium sulphate (DSS) was administered in mice via drinking water to induce colitis. Colon tissues were taken at days 2, 3, 4, 5, 6 and 7 from mice exposed to 2.5 % w/v DSS in drinking water. The mice of the recovery group were exposed to 2.5 % w/v DSS in the drinking water for 5 days and allowed to recover naturally for the next 5 days. On the tenth day, the colon tissue was collected from this group.
Assessment of Prolyl Hydroxylases (PHD) Levels
The colon tissue lysates were analysed for the level of protein expression of PHD-1, -2 and −-3 levels by a Western blotting technique as reported previously .
Disease Activity Index (DAI)
The weight of each animal was recorded on a daily basis. The stool consistency and appearance of faecal blood was monitored. These parameters were converted into the disease activity index (DAI) as illustrated previously .
The analysis of variance (ANOVA) or Student’s t test was employed for statistical comparisons and data was represented as mean ± standard deviation (mean ± SD).
RESULTS AND DISCUSSION
The upregulated PHD-1 in colonic biopsies of IBD patients illustrated the correlation between PHD1 expression and disease severity in patients [16, 19]. Among PHD-1, -2 and -3, only PHD-1 deficient mice were found to be selectively protected against DSS-induced colitis development advocating an affirmative function of PHD-1 in the management of intestinal epithelial cell apoptosis and preservation of epithelial barrier during intestinal inflammation . The hypothesised link between improved barrier function and consequent protection against the colitis development was also supported by studies performed in other models, indicating an antiapoptotic effect of pharmacologically inhibited hydroxylase enzyme [20, 21, 22].
These results suggest that PHD-3 isoform is expressed in healthy as well as the diseased colon tissue, indicating that PHD-3 is required for the normal function of the gut. However, PHD-1 and -2 expression levels fall when inflammation is initiated and gradually increases during the progression of inflammation and is observed to be the highest in chronic stages. The recovery group indicates that once the agent causing inflammation of the colon, i.e. DSS is removed from the drinking water, these mice show signs of recovery (Fig. 1); however, the increased levels of PHD-1 and -2 are not reduced to normal level, which suggest that PHD-1 and -2 are involved in chronic inflammatory stages of the disease. These findings advocate that inhibition of all PHDs using a non-selective prolyl hydroxylases inhibitor may not be the best strategy towards the development of new therapeutics for IBD. Hence, strategies to selectively target PHD-1 and -2 are warranted leading to an improved therapeutic advancement in the field of IBD treatment.
Compliance with Ethical Standards
All animal experiments were performed under UK Home Office personal and project licence.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Cummins, E.P., E. Berra, K.M. Comerford, A. Ginouves, K.T. Fitzgerald, F. Seeballuck, C. Godson, J.E. Nielsen, P. Moynagh, J. Pouyssegur, and C.T. Taylor. 2006. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proceedings of the National Academy of Sciences of the United States of America 103: 18154–18159.CrossRefGoogle Scholar
- 16.Tambuwala, M.M., E.P. Cummins, C.R. Lenihan, J. Kiss, M. Stauch, C.C. Scholz, P. Fraisl, F. Lasitschka, M. Mollenhauer, S.P. Saunders, P.H. Maxwell, P. Carmeliet, P.G. Fallon, M. Schneider, and C.T. Taylor. 2010. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139: 2093–2101.CrossRefGoogle Scholar
- 17.Khan, M.N., M.E. Lane, P.A. McCarron, and M.M. Tambuwala. 2018. Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function. Inflammopharmacology 26(2): 561–569. https://doi.org/10.1007/s10787-017-0364-x.CrossRefGoogle Scholar
- 22.Nangaku, M., Y. Izuhara, S. Takizawa, T. Yamashita, Y. Fujii-Kuriyama, O. Ohneda, M. Yamamoto, C. van Ypersele de Strihou, N. Hirayama, and T. Miyata. 2007. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2548–2554.CrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.